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ABSTRAK 
Latar belakang: 
Retinopati dan neuropati optik tnetupakan kesan sampingan yang telah dikenal pasti 
disebabkan oleh rawatan dengan tatnoxifen. Pemeriksaan dengan konfokal laser 
oftahnoskopi skan (Scanning confocal laser ophthalmoscopy) pada kepala saraf optik 
tncndapati saiz cawan optik yang lebih kecil di kalangan pcsakit yang mcncritna 
rawatan tamoxifen tanpa menunjukkan simtotn tnasalah penglihatan. Ujian 
elektrofisiologi n1en1pakan salah satu petneriksaan yang tidak invasifuntuk tnengkaji 
fungsi retina dan ujian ini boleh n1en1bezakan antara tnasalah kerosakan retina atau 
saraf optik. Kajian ini bertujuan untuk tnengkaji kesan a\val tatnoxifcn pada parameter 
kepala saraf optik dan elektrofisiologi di kalangan pcsakit tneneritna rawatan 
tarnoxifen. 
Kaedah: 
Ini merupakan kajian prospektif melibatkan jtnnlah 76 mata dari 38 orang pesakit 
kanser payudara yang tnenerima rawatan ubat tatnoxifcn di Hospital Universiti Sains 
Malaysia, Kelantan, Malaysia. Pesakit tnenjalani pen1eriksaan oleh hanya seorang 
doktor dan semua ujian dilakukan oleh seorang juruteknikal perubatan. Ketajatnan 
pcnglihatan, fungsi saraf optik, tnedan penglihatan, pemeriksaan mata, pengukuran 
paran1eter kepala saraf optik dengan Heidelberg Retinal Tomograph III (HRT III) dan 
corak potcnsi ransangan visual (pattern visual evoked potential) diperiksa ke atas 
pcsakit scbelutn dan 3 bulan selepas rawatan tatnoxifen dimulakan. 
Vl 
Keputusan: 
Didapati tiada kesan sampingan okular di kalangan pesakit selepas 3 bulan tnenerima 
rawatan tatnoxifen. Tahap ketajaman visual dan fungsi saraf optik tidak tnenunjukkan 
perubahan selepas rawatan. Tiada pen1bahan signifikan dikenalpasti dalan1 paratneter 
kepala saraf optik dan Iatensi P 100 dan mnp1itud pada ujian corak potensi rangsangan 
visual di kalangan pesakit selepas menerima tatnoxifen. 
Kesimpulan: 
Kesan toksik okular tnerupakan kesan satnpingan rawatan tatnoxifen. Optik neuropati 
disebabkan oleh tatnoxifen berkemungkinan sukar dibaikpulih dan metnberi kesan 
penglihatan yang tcruk. Jangka tnasa yang lebih panjang pcrlu untuk tnetncrhati kcsan 
tatnoxifen kcpada pcrubahan peringkat awal yang tnungkin berlaku ke atas saraf optik 
dan fungsi visualtnelalui ujian berkala dengan HRT III dan corak potensi ransangan 
visual (Pattern VEP). 
Vll 
ABSTRACT 
Background: 
Tan1oxifen retinopathy and optic neuropathy is a known complication of tatnoxifen 
treatment. Scanning confocal laser ophthahnoscopy of optic nerve head detnonstrated 
sn1aller optic cup in visually asymptomatic patients on tatnoxifen. Electrophysiology 
study is a non-invasive method of evaluating retinal function and facilitate 
differentiation between retinal and optic nerve dysfunction. The present study aitns to 
evaluate early optic nerve head paran1eter and electrophysiology changes in patients 
receiving tan1oxifen. 
Method: 
This is a prospective study involving 76 eyes of 38 breast cancer patients treated with 
Tamoxifen in Hospital Universiti Sains Malaysia, Kelantan, Malaysia. These patients 
'"'ere exatnined by a single doctor and the investigations were done by a single 
technician. The visual acuity, optic nerve function, visual field, anterior and posterior 
segtnent ocular exatnination, optic nerve head paratneters n1easure1nent on 1-Ieidelbcrg 
Retinal Ton1ograph III (HRT TIT) and Pattern VEP were assessed. The exmnination 
was performed before and three tnonths after treatment initiation. 
Vlll 
Results: 
There was no ta1noxifen ocular toxicity found 3 months post treatment with tamoxifen. 
There was no change in visual acuity and optic nerve function post treatment initiation. 
There were no statistically significant changes found in optic nerve head paran1eters 
on IIRT III and P 100 peak latency and mnplitude on PVEP within study duration. 
Conclusion: 
Ocular toxicity is a recognized con1plication of tamoxifen trcattnent. Tan1oxifen optic 
neuropathy is a potentially irreversible, visually disabling complication. Tatnoxifen 
ocular toxicity was not found 3 1nonths after tatnoxifen treattnent initiation atnong 
breast cancer patients. No early changes in optic nerve head paratneters and P 100 peak 
latency and atnplitudc changes found after 3 tnonths of treatment. Longer duration of 
tnonitoring \Vith HRT III and Pattern VEP tnay be needed to adequately observe for 
early, subclinical changes in optic nerve head parameters and visual function mnong 
tmnoxifen users. 
IX 
Chapter 1 
Introduction 
Tmnoxifen is a selective estrogen receptor modulator. It is used as a hormonal therapy 
in early invasive and advanced estrogen receptor (ER) positive breast cancer. 
Tamoxifen acts by competing with estrogen for estrogen receptor, prevents binding 
and halts the tutnour growth. The duration of treattnent with tamoxifen is cun·ently 
recon11nended for 5 years as it was found superior to shorter duration of period in 
itnproving survival rate. 
Tan1oxifen is also being used in treattnent of gyt1econ1astia, tnalignant tnelanotna, 
hepatocellular carcinon1a, and a chemopreventive agent for breast cancer prevention 
in high risk patients. 
The incidence of tatnoxifen related ocular toxicity were repotted as 6.3% and 12% in 
2 different prospective studies. Tamoxifen related ocular toxicities were repo1ted as 
co1neal subepithelial deposits, cataract, intraretinal refractile crystals and retinopathy, 
macular edema and optic neuritis. Systemic side effects include thromboembolism, 
memory itnpainnent, pretnature growth plate closure and increased risk of 
endotnetrial carcinoma. 
Detection of the ocular toxic effects before occuiTence of symptoms is of great value 
to prevent iiTeversible optic nerve damage. Regular ophthalmic exmnination which 
includes optic functions test (consists of visual acuity, visual field, colour vision, 
light brightness and red desaturation), ophthalmoscopy and photography has been 
used to detect ocular toxicity in the clinical practice. However, these asscssn1ents 
may not be useful in detecting subclinical tamoxifen-induced optic neuropathy or 
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retinopathy. With the advancetnent of technology, newer itnaging techniques and 
equipment provide the tools to examine the possibility of any early anatomical 
changes in the optic nerve head or early electrophysiology changes. 
Optic neuritis is a less comn1on but potentially irreversible visualtnorbidity frotn 
tatnoxifen ocular toxicity. It affects bilaterally and occur at range of 3 weeks to 7 
tnonths of tatnoxifen treattnent. Several case reports showed prolonged latency in 
patients with tatnoxifen induced optic neuritis. Visual evoked potential (YEP) is an 
electrophysiology test which is recognized as a sensitive tneasure of optic nerve 
pathologies. It is tnore sensitive for diagnosis of resolved optic neuritis than visual 
acuity, contrast sensitivity, Goldmann peritnetry or magnetic resonance itnaging. 
In a study by Eisner et. al. utilized confocal laser scanning ophthahnoscopy, optic 
cups of shoti tenn (less than 2 years) tamoxifen users were found to be significantly 
sn1aller in both the lateral and axial directions than the optic cups of control subjects 
whom are not using any hormonal medication. We are keen to evaluate possible 
early optic nerve head changes related to tamoxifen treattnent which may not be 
detectable clinically in routine ocular exatnination. 
The Heidelberg Retina Totnograph Ill (HRT Ill) is a confocal laser scanning system 
for acquisition and analysis of three-dimensional images of the posterior segment of 
the eye. Data frotn the HRT III can quantitatively describe the retinal topography and 
the follow-up topographic changes. Using a series of optical section itnages at 
different locations of a focal plane, a three-dimensional itnage is acquired. In 
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evaluation the optic nerve head, the HR T III provides optic nerve head parmneters 
(disc area, rim area, cup disc area ratio, cup volutne, disc volume and rim volume). 
In this study, we expect to observe possible early changes in the optic nerve head 
paran1eters. 
Visual Evoked Potential (VEP) is a cortical response to reflect generated by an 
electrical potential gradient recorded clinically by placing wire electrodes adjacent to 
the occipital cortex and to a non-visual area of the brain. It reflects the patency of 
visual pathway and to assess optic nerve function and its projection to the visual cortex. 
In pattern reversal VEP, the sthnulus used to generate the wave is an alten1ating high 
contrast checkerboard. 
A typical pattern-reversal VEP waveform consists of N75, PlOO and Nl35 peaks. 
These peaks are designated as negative and positive followed by the typical mean peak 
titne. The standard measure ofVEP atnplitude is the height ofPIOO from the preceding 
N75 peak. P 1 00 is usually a protninent peak that shows relatively little variation 
between subjects, tninilnal within-subject interocular difference, and minimal 
variation with repeated tneasurements over time. The responses stitnulate by these 
stin1uli have less intra- and inter-individual variability and tnore sensitivity in detecting 
tninor visual pathway abnonnality cotnparc to Flash YEP. In this study, we ain1 to 
evaluate for early changes in pattern YEP an1ong patients receiving tatnoxifcn 
treatment. 
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Chapter 2 
Study 
Protocol 
2.1 BACKGROUND 
Tamoxifen is an anti-estrogen medication. It is used as a hormonal therapy in early 
invasive and advanced Estrogen Receptor positive (ER positive) breast cancer1• In 
breast cancer, estrogen induces the proliferation of tumor cells and disease 
progression. It acts by con1peting with estrogen for its receptor, preventing estrogen 
binding and halts the tun1or growth2. The duration of treatment with Tatnoxifen is 
cutTently rccotntnended for 5 years as it is more superior to shorter duration of period 
in in1proving survival rate 1• 
Tatnoxifcn is also being used in treatn1ent of gynccotnastia, malignant n1clano1na. 
hepatocellular carcinoma. It is also being use as chetnopreventive agent for breast 
cancer prevention in high risk patients3• 
The incidences oftatnoxifen-related ocular toxicity were repot1ed as 6.3o/o and 12o/o in 
2 different prospective studies~· 5• Tatnoxifen related ocular toxicities \Vere repotted as 
cotneal subepithelial deposits, cataract, intraretinal refractile crystals and retinopathy, 
tnacular edetna and optic neuropathy-'- 10• Systetnic side effects include 
thron1boetnbolism, n1en1ory impaim1ent, pren1ature growth plate closure and increased 
risk of endotnetrial carcinotna. 
In a study by Eisner et. al optic cups of short term Tatnoxifen users (less than 2 years) 
were found to be significantly smaller in both the lateral and axial directions than the 
optic cups of control subjects whom are not using any hormonal medication. 11 
Optic neuritis is a less common but potentially irreversible visual morbidity from 
tatnoxifcn ocular toxicity. It affects bilaterally and occur at range of 3 weeks to 7 
6 
n1onths of tamoxifen treahnent9•10• Several case reports showed prolonged latency in 
patients with tamoxifen induced optic neuritis9·10. Visual evoked potential (VEP) is an 
electrophysiology test which is recognized as a sensitive tneasure of optic nerve 
pathologies. It is tnore sensitive for diagnosis of resolved optic neuritis than visual 
acuity, contrast sensitivity, Goldmann peritnetry or tnagnetic resonance itnaging12· 13 . 
Tan1oxifen toxic optic neuropathy was thought to be a rare side effect of trcattncnt. 
Ho\vever, it can cause potentially irreversible visual n1orbidity. We are keen to 
evaluate further for subclinical presentation oftamoxifen-related ocular toxicity which 
tnay not be detected in typical ocular exan1ination. Detection of the ocular toxic effects 
before occurrence of sytnptotns is of great value to prevent extensive optic nerve 
datnage and futihcnnore allow the complete recovery of nonnal function. 
The regular ophthalmic examination which includes optic functions test (consists of 
visual acuity, visual field, color vision, light brightness and red desaturation), 
ophthalmoscopy and photography has been used to detect ocular toxicity in the clinical 
practice. However, these assessments tnay not be useful in detecting subclinical 
Tan1oxifen-induced optic neuropathy or retinopathy. With the advancetnent of 
technology. newer itnaging techniques and equiptnent provide the tools to exatnine the 
possibility of any early anatotnical changes in the optic nerve head or possible 
electrophysiological changes. 
The Heidelberg Retina Totnograph III (HRT III) is a confocal laser scanning systen1 
for acquisition and analysis of three-ditnensional itnages of the posterior segn1ent of 
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the eye. Data fron1 the HRT III can quantitatively describe the retinal topography and 
the follow-up topographic changes. The typical application of the HRT III is the 
assesstnent of the glaucotnatous optic nerve head. Using a series of optical section 
itnages at different locations of a focal plane, a three-din1ensional itnage is acquired. 
In evaluation the optic nerve head, the 1-IRT III provides n1any details regarding the 
disc are, rim area, cup disc area ratio, cup volun1e, disc volun1e and rim volutnc. 
VEP is a cortical response to reflect generated by an electrical potential gradient 
recorded clinically by placing wire electrodes adjacent to the occipital cortex and to a 
non-visual area of the brain. It reflects the patency of visual pathway and to assess 
optic nerve function and its projection to the visual cortex. In pattern reversal VEP, 
the stimulus used to generate the wave is an alternating high contrast checkerboard. 
A typical pattern-reversal YEP wavefonn consists of N75, P 100 and N 135 peaks. 
These peaks are designated as negative and positive followed by the typical mean peak 
titne. The standard tneasure ofVEP an1plitude is the height ofP 100 from the preceding 
N75 peak. PI 00 is usually a prmninent peak that shows relatively little variation 
between subjects, n1initnal within-subject interocular difference, and tninimal 
variation with repeated tneasuretnents over titnc. The responses stitnulatc by these 
stitnuli have less intra- and inter-individual variability and tnore sensitivity in detecting 
tninor visual pathway abnonnality cotnpare to Flash YEP. 
In this study, we aim to evaluate the optic nerve head parameter changes and pattetn 
VEP changes atnong breast cancer patients pre-treattnent and 3 months of Tamoxifen 
treatment. 
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2.2 RATIONALE OF STUDY 
There are repotted cases of optic neuropathy and optic neuritis in patients receiving 
Tan1oxifen treatment1· 9• 10• Ashford et al. reported the reversibility of bilateral optic 
disc swelling upon treatn1ent cessation in a patient. Colley SM et al9• and Pugesgarrd 
T. et a1. 10 reported itnprovement of visual sytnpton1s in their patient \Vith optic 
neuropathy after cessation of treatment however in both cases, the sequele of optic 
atrophy and vision reduction were also reported. It is postulated that at most of the 
titne it is subclinical and not diagnosed by the typical optic nerve function test. 
Eisner et. al studies the optic cups of short term tatnoxifen users (less than 2 years) and 
found significantly smaller optic cups in both the lateral and axial directions than the 
optic cups atnong patients treated compared to control subjects whom arc not using 
any honnonaltnedication 11 • 
Tatnoxifen optic neuropathy reported to occur as early as 3 weeks after treatment 
initiation7. If the changes oftamoxifen-induced optic neuropathy can be detected early 
in the course of treattnent, it may be possible in preventing the possible pennanent 
datnage to optic nerve and the potential outcon1e of irreversible vision reduction. 
The aim of this study is to evaluate early changes in optic nerve head paratneters and 
the electrophysiology test using HRT III and pattern YEP among breast cancer patients 
treated with tamoxifen in Hospital Universiti Sains Malaysia (HUSM). 
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2.3 RESEARCH OBJECTIVE 
2.3.1 General Objective 
To study the optic nerve head parmneters and ocular electrophysiology among breast 
cancer patients on tan1oxifen treatment. 
2.3.2 Specific Objectives 
1. To evaluate the optic nerve head parameters using 1-IRT III pre and 3 tnonths 
of trcatn1ent with tamoxifen atnong breast cancer patients. 
11. To evaluate the pattern visual evoked potential pre and 3 tnonths of treattnent 
with tan1oxifen among in breast cancer patients. 
2.4 RESEARCH QUESTIONS 
1. Is there significant change in optic nerve head parameters in HRT III pre and 
3 months of treatment with tatnoxifen in breast cancer patients? 
n. Is there a significant change in pattern visual evoked potential pre and 3 months 
of treatment with tamoxifen in breast cancer patients? 
2.5 RESEARCH HYPOTHESIS 
1. There is a significant change in optic nerve head paratncters in HR T III pre and 
3 tnonths after treattnent with tatnoxifen in breast cancer patients 
11. There is significant change in pattern visual evoked potential after treattnent 
with tamoxifen in breast cancer patients. 
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2.6 METHODOLOGY 
2.6.1 Study Design 
Cross-Sectional Study 
2.6.2 Study Location 
Eye Clinic, Hospital Universiti Sa ins Malaysia (I Iospital USM) 
2.6.3 Study Duration 
January 2015- May 2016 
2.6.4 Study Reference Population 
Patients diagnosed with breast cancer in Malaysia 
2.6.5 Source population 
Patients diagnosed \Vith breast cancer and are planned for tamoxifen treatment 
in Hospital Universiti Sains Malaysia (HUSM) 
2.6.6 Sampling Frame 
Patients diagnosed with breast cancer in HUSM and planned for tatnoxifcn trcattncnt 
frotn January 2015 till May 2016 
1 l 
2.6. 7 Inclusion and Exclusion Criteria 
Inclusion Criteria: 
- Breast cancer patients whom are planned for tatnoxifen treatlncnt 
- Patients aged 18 years old and above 
Exclusion Criteria: 
- Patients with underlying ocular diseases 
Cornea opacity or presence of dense ocular opacity 
- Patients with abno1mal HRT Ill or patte1n VEP on first tilne evaluation 
before treah11ent 
Patients with Diabetes Me11itus, Hypertension or renal itnpain11ent 
- Patients with past history of intake of other neurotoxic drug 
Mentally challenged patients 
- Developtnental brain disease or brain tnetastasis 
- Acti vc brain disease 
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2.6.8 Sample Size Calculation 
Objective 1 and Objective 2: Literature reviews on the tnean and SD for optic nerve 
head paratneters, pattern VEP in breast cancer patients on tan1oxifen treattnent were 
not found. 
Satnple size was calculated using G*Power 3.1.9.2 
T tests- Dependent T-test, within factor, with medium size effect (Cohen, 1988) 
Tails =two 
Effect size =0.5 
a err prob =0.05 
Power ( 1-P err prob) =0.80 
Number of groups = 1 
Nonsphericity COITection E =2.92 
Critical t =2.03 
Df = 33 
Total sample size =34 
Estitnated I Oo/o of drop-out: 
Total sample size, n = 34/ ( l-0.1) 
=38 
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2.6.9 Sampling Method 
Non-probability sample selection of all breast cancer patients attending Eye 
Clinic, Hospital USM 
2.6.10 Examination Procedure 
The study will be conducted after obtaining approval frotn the lltunan 
Research Ethics Comn1ittce USM (1-IREC). 
1. The study will be conducted in the Eye Clinic of Hospital Universiti Sains 
Malaysia between January 2015 and May 2016. 
2. Patients \Vho fulfill the inclusion and exclusion criteria will be invited to 
pat1icipate. Infonned written consent \Vill be obtained frotn patient. 
3. In the Eye Clinic, distance visual acuity will be tneasured tnonocularly using a 
Snellen chatt for distance (Reichert, NY, USA) at 6 meters 
4. A cotnprehensive eye examination, including pupillary examination, optic 
nerve function tests, Humphrey visual field test and slit lamp bion1icroscopy 
wi11 be perfonned to rule out any associated ocular conditions which would 
have precluded participation in the study. 
5. Intraocular pressure will be assessed with applanation tonometry. 
6. After dilation with topical Phenylephrine 2.5% and Tropicatnide 1 o/o, fundus 
will be examined using a slit lamp bio tnicroscopy and a 90 D condensing lens 
or binocular indirect ophthalmoscope (BIO) and a 20 D condensing lens by 
principle investigator. 
7. Bilateral fundus photograph wi11 be captured by one identified trained tnedical 
operator using a digital fundus catnera. 
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8. Optic nerve head paratneters will be captured by one identified trained tnedical 
operator using Heidelberg Retinal Tomograph III (Heidelberg Engineering, 
Getmany). Both eyes optic nerve head itnage will be acquired three-
dimensionaly \Vith the pre-detennined acquisition paratneters. The size of the 
field of view is fixed at 15° x 15°, and the digitization is perfon11cd in frames 
of384 x 384 pixels. The mean topography in1ages are con1puted auton1atically. 
The operator will draw the contour line tnanually using both the reflectance 
and topography in1age as guide for placen1ent of contour line. Contour line will 
be drawn at the inner edge of the scleral ring. A good quality itnage will be 
considered when the following criteria are fulfilled: 1) the optic disc in1age 
appeared centrally. 2) tninitnal eye tnovetnent detected during itnage capture, 
3) absence of artifact and 4) topography standard deviation less than 50 
tnicrotneters. The Overall Quality Score frotn the software cotnbines Image 
and Itnaging Quality Score to determine quality of image. Only images with 
good and acceptable overall quality score will be used for analysis. 
9. Pattern VEP recording will be done using Granzfield PVEP (Roland-Consult, 
RETT-port 32, Gertnany). Recording will be based on standard ISCEV PVEP 
protocol 2009 15.The placetnent of electrode is based on the "I 0-20 
International Systetn" in proportion to the size of the head. Patient was asked 
to sit at l.Stn frotn the video tnonitor. PVEP was tested tnonocular with 
appropriate refractive cotl'ection. The test was elicited by checkerboard stimuli 
with large 1° (60 min of arc) checks. Peak latency ofPIOO, N75 and Nl35; and 
amplitude ofN75- PIOO and PIOO- N135 will be measured 
I 0. Statistical analyses will be performed using SPSS version 22.0. Paired T -test 
wi11 be perfonned to detem1ine the changes of optic nerve head paratneters, 
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respective latencies and amplitudes of pattern VEP pre and 3 tnonths of 
Tamoxifen treatment. 
2.6.11 Research Tools 
I. Snellen chart for distance (Reichert, NY, USA) 
2. Slit Latnp Biotnicroscopy (Clement Clark lnten1ational, UK ) with 90D and 
78D lenses (Yolk, USA) 
3. Binocular Indirect Ophthahnoscope (Heine, Gern1any) with 200 and 28D 
lenses (Yolk, USA) 
4. Digital Retinal Camera (VX-1 0/KOW A/Japan) 
5. Hutnphrey Visual Field Analyzer Statpac2 (Carl Zeiss Meditec Inc, USA). 
6. Heidelberg Retinal Tomograph III (Heidelberg Engineering, Gcm1any) 
7. Granzfield PVEP (Roland-Consult, RETI-port 32, Gennany) 
8. Gutt Tropicatnide 1% 
9. Gutt Phenyl epinephrine 2.5% 
I 0. Gutt Proparacaine 0.5% 
2.6.12 Statistical Analysis 
All data will be entered and analyzed using SPSS version 22.0. For descriptive 
statistics, data will he presented by tnean (SD) for nu1nerical variables and frequency 
(percentage) for categorical variables. For objective number 1 and 2, we will use paired 
T -test for analysis to cotnpare means of variables. 
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2.6.13 Ethical Considerations 
This study will be submitted to the Ethical Committee ofUSM. An information 
form will be given to all patticipants prior to data collection. Written consent will be 
obtained frotn the patient. 
2.6.14 Flolv Chart 
Breast Cancer Patients Planned for Tatnoxifen 
Treattnent in HUSM 
Inclusion Criteria/Exclusion Criteria 
Before Starting Treatlnent 
Informed Consent 
! Before Starting Treattnent 
Con-ected VA test (Snellen chat1), Baseline ocular examinations and optic nerve 
functions, Optic nerve head paran1eters tneasurement and PVEP tneasuretnent 
1 3 Months ofTamoxifen Treatment 
Corrected VA test (Snellen chart), ocular examinations and optic nerve functions, 
Optic nerve head paran1eters tneasurement and PVEP tneasuren1ent 
l 
Data Collection 
1 
Data Analysis 
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2.6.15 Dummy Tables 
Objective 1: Optic nerve head paran1eters using HRT III pre and 3 tnonths oftreatn1ent 
with Tamoxifen among breast cancer patients. 
Right eye 
Variables 
Disc area 
Cup area 
Ritn area 
Cup volutne 
Rim volutnc 
Cup disc area 
ratio 
Mean cup 
depth 
Maximum 
cup depth 
Cup shape 
measure 
Height 
variation 
contour 
Mean RNFL 
thickness 
RNFL cross 
section area 
Pre Post Mean Difference t-statistics P value 
Mean (SD) (95%) Cl) (df) 
18 
Left eye 
Variables 
Disc area 
Cup area 
Rin1 area 
Cup volutne 
Rim volume 
Cup disc area 
ratio 
Mean cup 
depth 
Maxitnutn 
cup depth 
Cup shape 
measure 
Height 
variation 
contour 
Mean RNFL 
thickness 
RNFL cross 
section area 
Pre Post Mean Difference t-statistics P value 
Mean (SD) (95% Cl) (df) 
19 
Objective 2: To evaluate the pattern visual evoked potential pre and 3 months of 
treatment with Tamoxifen among in breast cancer patients. 
Right eye 
Variables 
NI Latency 
PI Latency 
N2 Latency 
Nl PI 
An1plitude 
PI N2 
Atnplitude 
Left eye 
Variables 
NI Latency 
PI Latency 
N2 Latency 
Nl PI 
An1plitudc 
PI N2 
An1plitude 
Pre Post Mean Difference t-statistics P value 
Mean (SD) (95% CI) (df) 
Pre Post Mean Difference t-statistics P value 
Mean (SD) (95% Cl) (df) 
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2.7 GANTT CHART 
20 15 I 2016 
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Data 
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Data 
analysis 
Report 
writing ~ 
Submission 
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